Navigation Links
EXL Announces Appointment of Rembert de Villa as Head of Transformation Services
Date:4/14/2008

.

This press release contains forward-looking statements. You should not place undue reliance on those statements because they are subject to numerous uncertainties and factors relating to the Company's operations and business environment, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking statements include information concerning the Company's possible or assumed future results of operations, including descriptions of its business strategy. These statements often include words such as "may," "will," "should," "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions. These statements are based on assumptions that we have made in light of management's experience in the industry as well as its perceptions of historical trends, current conditions, expected future developments and other factors it believes are appropriate under the circumstances. You should understand that these statements are not guarantees of performance or results. They involve known and unknown risks, uncertainties and assumptions. Although the Company believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect the Company's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors are discussed in more details in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2007. These risks could cause actual results to differ materially from those implied by forward-looking statements in this release.

You should keep in mind that any forward-looking statement made herein, or elsewhere, speaks only as of the date on which it is made. New risks and uncertainties come up from time to time, and it is impossible to predict these events or
'/>"/>

SOURCE ExlService Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Botaneco Announces Launch of Second Generation Oleosome Product
2. YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR TWO OF ITS ANTI-CANCER DRUGS AT AACR ANNUAL MEETING
3. Signalife Announces Webcast
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. ARIUS announces first quarter fiscal 2008 financial results
6. AEterna Zentaris Announces Changes to its Management Team
7. Vermillion Announces Appointment of John Hamilton to Board of Directors
8. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
9. Amnis Announces Release of Powerful New Image Data Analysis Software
10. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
11. Medicsight Announces Chinese State Food and Drug Administration Approval for MedicRead Colon Workstation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Health care employment grew ...he only one to show consistent growth during the U...itals remain in trouble, and health systems are co...onnel, instead of just administrators. , ...h care employment continued growing in October des...
(Date:11/24/2009)..., SHANGHAI,Nov.24/PRNewswire-Asia/--NODPharmaceuti...PTO)hasallowedthepatentapplicationfor,itsnano-part...ogyisahighlyefficientapproachtoincorporatepeptides...raldeliveryofdrugs,otherwiseadministeredasinjectio...liedtomanymacromoleculardrugssuchasinsulin,interfe...
(Date:11/24/2009)..., SHANGHAI,Nov.24/PRNewswire-Asia/--ShanghaiBiolax...ion(SFDA)hasapprovedthe,investigationalnewdrugappl...novativeinsulinformulationtotreatdiabetes.ThisIND,...calstudy. , Diabetesisadisordercharacteristic...onsofdiabetesoftenresultinseveremicro-and,macro-va...
(Date:11/24/2009)... The FBI recently approved the ...ries participating in or generating DNA records fo... Madison, WI USA (PRWEB) -- The FBI recen...tem for use by laboratories participating in, or ... System (NDIS). NDIS currently contains more than ...
Breaking Biology Technology:The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Biolaxy Secures IND Approval for Oral Insulin 2NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2
...ONDON, Aug. 27 Following the successful acquisiti...ry, Chiltern, a leading,contract research organiza... its two early Phase units into a single operation... Phase is providing high quality early phase servi...ll established units in Slough,(just outside of Lo...
...AN DIEGO and INDIANAPOLIS, Aug. 26 Amylin,Pharmac...Company (NYSE: LLY ),in a conference call today p...ng the August 18, 2008 U.S. Food and Drug Administ... (exenatide) injection referencing,pancreatitis. T...referenced,in the alert, as well as others, and pr...
...otes Secured by Royalties on U.S. Sales of SANCTUR...26 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV )...ement to institutional investors of $105.0 million...e secured by royalties to be,paid from sales in th...,(trospium chloride). SANCTURA and SANCTURA XR are...
Other Biology Technology:Chiltern Early Phase: Fully Integrated and Business Ready 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 4Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 5Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 6Indevus Announces Private Placement of $105 Million of Non-Recourse Notes 2Indevus Announces Private Placement of $105 Million of Non-Recourse Notes 3Indevus Announces Private Placement of $105 Million of Non-Recourse Notes 4
(Date:11/23/2009)...ciated strain of the deadly superbug MRSAan infect...bioticsposes a far greater health threat than prev... according to a study in the December issue of Em...s easily picked up in fitness centers, schools, an...l burden of MRSA within hospitals, the report foun...
(Date:11/23/2009)...gests that a common oral bacterium may exacerbate ... et al, "Unique Lipids from a Common Human Bacteri...f Enhancing Autoimmunity," appears in the December.... , Multiple sclerosis (MS), a disease where the...affects nearly 1 in 700 people in the United State...
(Date:11/23/2009)... University of Alabama at Birmingham (UAB) researc...ing medical conditions (co-morbidity) do not expla...mericans compared to Caucasians who also have colo... Cancer , a journal of the American Cancer Societ... co-morbidity are independent predictors of poor s...
Breaking Biology News(10 mins):New study finds MRSA on the rise in hospital outpatients 2Factors from common human bacteria may trigger multiple sclerosis 2Racial disparity in colon cancer survival not easily explained, UAB researchers say 2VIASPACE Pursuing Renewable Energy Business in Asia 13353 1VIASPACE Pursuing Renewable Energy Business in Asia 13353 2VIASPACE Pursuing Renewable Energy Business in Asia 13353 3Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 1Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 2Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 3Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 4Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 5Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures 13351 6Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 1Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 2Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 3Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 4Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 5Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 6Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 7Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 8Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 9Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 10Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 11Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 12Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 13Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 14Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 15Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 16Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 17Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 18Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 19Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 20Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 21Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 22Valeant Pharmaceuticals Reports Second Quarter Financial Results 53602 23
...veling the complex mechanisms in the brain that re...etites are controlled by systems very similar to t...type of neuron that is essential for feeding behav... and undergo rapid weight loss. , Remarkably, th...only influenced eating behavior when they were rem...
...des insight into genetic basis of human diseaseHig...lds a map of genetic variation which can give clue...he current technologies collect genotypes, or info...t many scientists believe that drilling down to th... of each chromosome -- so-called haplotypes -- wil...
...he last ice age are the likely culprits in the ext...rican great mammals such as mammoths, mastodons an...da researcher. , Determining whether the first arr...inent at the end of the last Ice Age was responsib...d scientists because both events occurred at the s...
Other Biology News:An essential regulator of body weight revealed 2An essential regulator of body weight revealed 3An essential regulator of body weight revealed 4California computer scientists double volume of data in NIH biotech repository 2California computer scientists double volume of data in NIH biotech repository 3California computer scientists double volume of data in NIH biotech repository 4Study shows big game hunters, not climate change, killed off sloths 2Study shows big game hunters, not climate change, killed off sloths 3
Rabbit Anti-Schizosaccharomyces pombe SpUlp2 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Human STX18 Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Anti-Human sRANKL Polyclonal Antibody, Biotin Conjugated from Cell Sciences
Mouse Anti-CD42d Monoclonal Antibody, Unconjugated, Clone CLB-SW16 (formerly 708) from Abcam
Biology Products: